Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Finerenone in Renal Impairment
NCT04908436Phase 1Completed
- Sponsor
- Bayer
- Start
- Oct 2010
- Primary completion
- May 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of finerenone in chronic heart failure (CHF) and chronic kidney disease (CKD) (4 arms), sponsored by Bayer. Primary endpoints: Area under the plasma concentration vs time curve at 96 hours, Maximum plasma concentration at 96 hours and 2 more. Started Oct 2010; status: completed.
02
Drugs
finerenone
03
Conditions
chronic heart failure (CHF)chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT04908436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04908436.